A Phase 4 interventional study of HCTZ + Amlodipine and Valsartan/HCTZ in Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 5 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-05-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.
Among the 140 studies testing valsartan in Hypertension, this one is the 45th largest by enrollment of the 139 interventional ones that give a count, is one of 23 that started in 2006, is one of 67 in phase 4, and was the 76th registered.
6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.
Browse Hypertension studies →None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →
Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
140 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 5 · Phase 3 54 · Phase 4 67
First in 2001; this study’s year is marked. 23 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 412 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 198 across the 139 interventional studies. Of the 126 that completed or were terminated, 29 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 140 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
227 studies in Hypertension by Novartis: 4 open now, 5 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 227 studies in Hypertension by Novartis, this one is the 90th largest by enrollment of the 222 interventional ones that give a count, is one of 32 that started in 2006, is one of 67 in phase 4, and was the 115th registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 140 studies testing valsartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 227 in Hypertension:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the blood pressure lowering efficacy of valsartan/hydrochlorothiazide (HCTZ) compared to hydrochlorothiazide for the treatment of obese hypertensive (mean sitting systolic blood pressure [MSSBP] >150 mmHg) patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Valsartan/HCTZ
Drug: HCTZ + Amlodipine
Drug pages: Hydrochlorothiazide · Amlodipine
* 12.5 mg HCTZ capsules * 25 mg HCTZ capsules * 5 mg amlodipine capsules * 10 mg amlodipine capsules
Drug pages: Valsartan · Hydrochlorothiazide
* 160 mg film-coated valsartan tablets * 320 mg film-coated valsartan tablets * 12.5 mg HCTZ capsules * 25 mg HCTZ capsules
Change in Mean Sitting Systolic Blood Pressure (MSSBP)
Time frame: Baseline to Week 8
Change in Mean Sitting Diastolic Blood Pressure (MSDBP)
Time frame: Baseline to Weeks 4, 8, 12 and 16
Number of Patients Achieving Blood Pressure (BP) Control by Visit (< 140/90 mm Hg)
Mean sitting systolic blood pressure/mean sitting diastolic blood pressure \< 140/90 mm Hg
Time frame: Weeks 4, 8, 12 16 and End of Study (for patients that did not complete the last visit at week 16)
Number of Patients Achieving Blood Pressure (BP)Control by Visit (< 130/80 mm Hg)
Mean sitting systolic blood pressure/mean sitting diastolic blood pressure \< 130/80 mm Hg
Time frame: Week 4, 8, 12, 16, End of Study (for patients that did not complete the last visit at week 16)
Change From Baseline in Postprandial Glucose
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test
Time frame: Week 16
Change From Baseline in Postprandial Insulin
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test
Time frame: Week 16
Change From Baseline in Postprandial Non-esterified Fatty Acids
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test
Time frame: Week 16
| Milestone | Valsartan/HCTZ (Hydrochlorothiazide) | HCTZ +Amlodipine |
|---|---|---|
| Started | 206 | 206 |
| Completed | 170 | 178 |
| Not completed | 36 | 28 |
| Withdrew: Withdrawal by subject | 16 | 13 |
| Withdrew: Adverse event | 6 | 4 |
| Withdrew: Lost to follow-up | 5 | 6 |
| Withdrew: Protocol violation | 6 | 3 |
| Withdrew: Lack of efficacy | 2 | 2 |
| Withdrew: Abnormal lab values | 1 | 0 |
| mm Hg | Valsartan/HCTZ (Hydrochlorothiazide) | HCTZ +Amlodipine |
|---|---|---|
| Baseline | 159.7 ± 7.81 | 159.0 ± 7.62 |
| Week 8 | 131.2 ± 16.26 | 137.5 ± 13.52 |
| Change from baseline | -28.6 ± 15.61 | -21.5 ± 12.58 |
| mm Hg | Valsartan/HCTZ (Hydrochlorothiazide) | HCTZ +Amlodipine |
|---|---|---|
| Baseline | 94.9 ± 7.94 | 93.6 ± 8.18 |
| Week 4 | 85.7 ± 9.38 | 87.6 ± 9.20 |
| Week 8 | 81.9 ± 9.87 | 85.1 ± 8.54 |
| Week 12 | 81.1 ± 9.14 | 82.8 ± 8.75 |
| Week 16 | 80.8 ± 10.14 | 80.9 ± 8.66 |
| Change from baseline to week 16 | -14.0 ± 9.90 | -12.7 ± 8.35 |
Mean sitting systolic blood pressure/mean sitting diastolic blood pressure \< 140/90 mm Hg
| participants | Valsartan/HCTZ (Hydrochlorothiazide) | HCTZ +Amlodipine |
|---|---|---|
| Week 4 | 91 | 69 |
| Week 8 | 123 | 102 |
| Week 12 | 122 | 112 |
| Week 16 | 124 | 140 |
| End of study | 133 | 146 |
Mean sitting systolic blood pressure/mean sitting diastolic blood pressure \< 130/80 mm Hg
| participants | Valsartan/HCTZ (Hydrochlorothiazide) | HCTZ +Amlodipine |
|---|---|---|
| Week 4 | 33 | 18 |
| Week 8 | 59 | 23 |
| Week 12 | 57 | 46 |
| Week 16 | 62 | 65 |
| End of Study | 68 | 68 |
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test
| mg/dL | Valsartan/HCTZ (Hydrochlorothiazide) | HCTZ +Amlodipine |
|---|---|---|
| Baseline visit (0 minutes) | 98.0 ± 15.91 | 99.4 ± 19.12 |
| Week 16 (0 minutes) | 98.1 ± 15.68 | 102.8 ± 17.81 |
| Change from baseline to week 16 (0 minutes) | -0.5 ± 13.71 | 3.4 ± 18.28 |
| Baseline visit (120 minutes) | 123.9 ± 47.18 | 127.7 ± 40.30 |
| Week 16 (120 minutes) | 126.3 ± 49.52 | 146.5 ± 56.51 |
| Change from baseline to week 16 (120 minutes) | 2.1 ± 38.21 | 18.9 ± 40.88 |
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test
| mg/dL | Valsartan/HCTZ (Hydrochlorothiazide) | HCTZ +Amlodipine |
|---|---|---|
| Baseline visit (0 minutes) | 19.66 ± 20.435 | 20.37 ± 20.583 |
| Week 16 (0 minutes) | 23.45 ± 26.039 | 23.62 ± 19.267 |
| Change from baseline to week 16 (0 minutes) | 3.41 ± 28.427 | 3.67 ± 19.170 |
| Baseline visit (120 minutes) | 92.04 ± 82.183 | 95.95 ± 76.483 |
| Week 16 (120 minutes) | 116.04 ± 129.880 | 120.01 ± 100.302 |
| Change from baseline to week 16 (120 minute) | 24.68 ± 90.094 | 28.07 ± 71.674 |
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test
| mg/dL | Valsartan/HCTZ (Hydrochlorothiazide) | HCTZ +Amlodipine |
|---|---|---|
| Baseline visit (0 minutes) | 0.45 ± 0.208 | 0.47 ± 0.318 |
| Week 16 (0 minutes) | 0.46 ± 0.194 | 0.47 ± 0.196 |
| Change from baseline to week 16 (0 minutes) | 0.01 ± 0.249 | 0.00 ± 0.341 |
| Baseline visit (120 minutes) | 0.11 ± 0.090 | 0.10 ± 0.116 |
| Week 16 (120 minutes) | 0.10 ± 0.093 | 0.10 ± 0.056 |
| Change from baseline to week 16 (120 minutes) | -0.01 ± 0.117 | -0.01 ± 0.120 |
| Age, Customized(participants) | Valsartan/HCTZ (Hydrochlorothiazide) | HCTZ +Amlodipine | Total |
|---|---|---|---|
| < 65 years | 172 ± 83.5 | 180 ± 87.4 | 352 ± 85.4 |
| >=65 years | 34 ± 16.5 | 26 ± 12.6 | 60 ± 14.6 |
| Sex: Female, Male(Participants) | Valsartan/HCTZ (Hydrochlorothiazide) | HCTZ +Amlodipine | Total |
|---|---|---|---|
| Female | 124 | 148 | 272 |
| Male | 82 | 58 | 140 |
The record gives a start of Dec 2006 and a primary completion of Nov 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2009, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Valsartan · Hydrochlorothiazide